Neutropenia in patients under treatment with clozapine and COVID-19 infection

Introduction Clozapine is among the most effective antipsychotics used for treatment resistant schizophrenia. Adverse reactions to clozapine include neutropenia. Case series report that clozapine-treated patients with COVID-19 have no documented neutropenia. Objectives We sought to investigate t...

Full description

Bibliographic Details
Published in:European Psychiatry
Main Authors: S. Bonaccorso, A. Ricciardi, S. Ouabbou, C. Theleritis, A. Ross-Michaelides, A. Metastasio, N. Stewart, M. Mohammed, F. Schifano
Format: Article
Language:English
Published: Cambridge University Press 2021-04-01
Subjects:
Online Access:https://www.cambridge.org/core/product/identifier/S092493382101796X/type/journal_article
_version_ 1850093093942984704
author S. Bonaccorso
A. Ricciardi
S. Ouabbou
C. Theleritis
A. Ross-Michaelides
A. Metastasio
N. Stewart
M. Mohammed
F. Schifano
author_facet S. Bonaccorso
A. Ricciardi
S. Ouabbou
C. Theleritis
A. Ross-Michaelides
A. Metastasio
N. Stewart
M. Mohammed
F. Schifano
author_sort S. Bonaccorso
collection DOAJ
container_title European Psychiatry
description Introduction Clozapine is among the most effective antipsychotics used for treatment resistant schizophrenia. Adverse reactions to clozapine include neutropenia. Case series report that clozapine-treated patients with COVID-19 have no documented neutropenia. Objectives We sought to investigate the potential adverse effect of coronavirus disease (COVID-19) in patients taking clozapine. Methods We retrospectively inspected data of 13 consecutive patients on clozapine, admitted to Highgate Mental Health Centre -Camden & Islington NHS Foundation Trust between March and June 2020. Selection was based on their COVID-19 symptoms presentation and/or COVID-19 positive test. We used a linear regression model with COVID status as independent variable and absolute neutrophil count (ANC) as dependent variable to inform about a correlation between COVID-19 status and neutrophil count. STATA was used for statistics. Results We collected data on thirteen patients of which nine were male. The median age was of 41.97 years; six subjects were Black, three were Asian and four were White Caucasian. Ten subjects tested positive to COVID-19 and 3 were suspected cases -these latter were excluded from stastical analysis. During COVID-19 infection, neutrophils count (ANC) dropped significantly to 4.215 from a baseline value of 5.337. The beta values of 0.83 shows that ANC declined significantly during COVID-19 infection (p =<.0001, R2 = 95%). In three of thirteen patients, ANC drop was significant and changed the patients’ monitoring status from green to amber and required frequent blood tests. Conclusions Clinicians should bear in mind that a significant drop in neutrophils count may occur in COVID-19 -infected patients taking clozapine. Disclosure No significant relationships.
format Article
id doaj-art-e43aeb93b4d349569318047a2a31e894
institution Directory of Open Access Journals
issn 0924-9338
1778-3585
language English
publishDate 2021-04-01
publisher Cambridge University Press
record_format Article
spelling doaj-art-e43aeb93b4d349569318047a2a31e8942025-08-20T00:08:07ZengCambridge University PressEuropean Psychiatry0924-93381778-35852021-04-0164S677S67710.1192/j.eurpsy.2021.1796Neutropenia in patients under treatment with clozapine and COVID-19 infectionS. Bonaccorso0A. Ricciardi1S. Ouabbou2C. Theleritis3A. Ross-Michaelides4A. Metastasio5N. Stewart6M. Mohammed7F. Schifano8Highgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London, United KingdomHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London, United KingdomHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London, United Kingdom1st Psychiatry Dept, National and Kapodistrian University of Athens, Athens, GreeceHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London, United KingdomHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London, United KingdomHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London, United KingdomHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London, United KingdomPsychiatry And Psychopharmacology, University of Hertfordshire, Hertfordshire, United Kingdom Introduction Clozapine is among the most effective antipsychotics used for treatment resistant schizophrenia. Adverse reactions to clozapine include neutropenia. Case series report that clozapine-treated patients with COVID-19 have no documented neutropenia. Objectives We sought to investigate the potential adverse effect of coronavirus disease (COVID-19) in patients taking clozapine. Methods We retrospectively inspected data of 13 consecutive patients on clozapine, admitted to Highgate Mental Health Centre -Camden & Islington NHS Foundation Trust between March and June 2020. Selection was based on their COVID-19 symptoms presentation and/or COVID-19 positive test. We used a linear regression model with COVID status as independent variable and absolute neutrophil count (ANC) as dependent variable to inform about a correlation between COVID-19 status and neutrophil count. STATA was used for statistics. Results We collected data on thirteen patients of which nine were male. The median age was of 41.97 years; six subjects were Black, three were Asian and four were White Caucasian. Ten subjects tested positive to COVID-19 and 3 were suspected cases -these latter were excluded from stastical analysis. During COVID-19 infection, neutrophils count (ANC) dropped significantly to 4.215 from a baseline value of 5.337. The beta values of 0.83 shows that ANC declined significantly during COVID-19 infection (p =<.0001, R2 = 95%). In three of thirteen patients, ANC drop was significant and changed the patients’ monitoring status from green to amber and required frequent blood tests. Conclusions Clinicians should bear in mind that a significant drop in neutrophils count may occur in COVID-19 -infected patients taking clozapine. Disclosure No significant relationships. https://www.cambridge.org/core/product/identifier/S092493382101796X/type/journal_articleclozapineCOVID-19neutropeniaschizophrénia
spellingShingle S. Bonaccorso
A. Ricciardi
S. Ouabbou
C. Theleritis
A. Ross-Michaelides
A. Metastasio
N. Stewart
M. Mohammed
F. Schifano
Neutropenia in patients under treatment with clozapine and COVID-19 infection
clozapine
COVID-19
neutropenia
schizophrénia
title Neutropenia in patients under treatment with clozapine and COVID-19 infection
title_full Neutropenia in patients under treatment with clozapine and COVID-19 infection
title_fullStr Neutropenia in patients under treatment with clozapine and COVID-19 infection
title_full_unstemmed Neutropenia in patients under treatment with clozapine and COVID-19 infection
title_short Neutropenia in patients under treatment with clozapine and COVID-19 infection
title_sort neutropenia in patients under treatment with clozapine and covid 19 infection
topic clozapine
COVID-19
neutropenia
schizophrénia
url https://www.cambridge.org/core/product/identifier/S092493382101796X/type/journal_article
work_keys_str_mv AT sbonaccorso neutropeniainpatientsundertreatmentwithclozapineandcovid19infection
AT aricciardi neutropeniainpatientsundertreatmentwithclozapineandcovid19infection
AT souabbou neutropeniainpatientsundertreatmentwithclozapineandcovid19infection
AT ctheleritis neutropeniainpatientsundertreatmentwithclozapineandcovid19infection
AT arossmichaelides neutropeniainpatientsundertreatmentwithclozapineandcovid19infection
AT ametastasio neutropeniainpatientsundertreatmentwithclozapineandcovid19infection
AT nstewart neutropeniainpatientsundertreatmentwithclozapineandcovid19infection
AT mmohammed neutropeniainpatientsundertreatmentwithclozapineandcovid19infection
AT fschifano neutropeniainpatientsundertreatmentwithclozapineandcovid19infection